Update: Alzheimer’s study cancelled
Update:
The Generation Program Alzheimer’s disease prevention studies planned by Okanagan Clinical Trials (OCT) in Kelowna has been cancelled.
“After an assessment of unblinded data during a regular pre-planned review, the Generation Program sponsors made the decision to discontinue investigation of the BACE1 inhibitor CNP520 (umibecestat).
“The sponsors concluded that the potential benefit for participants in the studies did not outweigh the risk,” said a release from OCT sned to Vernon Matters.











